Skip to main content
Livermore
Livermore
ZHEN

Perceptive Advisors LLC

SEC CIK
0001224962
Latest filing
Aug 14, 2026

The latest 13F from Perceptive Advisors LLC covers Q2 2026 (filed Aug 14, 2026): 102 long positions worth $6.44B. The top 10 holdings make up 48.9% of the portfolio, and the largest is Praxis Precision Medicines, Inc. (PRAX) at 10.6%. Livermore has 35 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
21
Est. +$586.1M
Added
30
Est. +$517.2M
Reduced
28
Est. −$429.8M
Sold out
11
Est. −$343.7M

Top 5 holdings

Share of this quarter's portfolio value

  1. PRAXPraxis Precision Medicines, Inc.
    10.6%$681.6MHistory
  2. SYRESpyre Therapeutics, Inc.
    6.0%$383.5MHistory
  3. CELCCelcuity Inc.
    5.2%$334.5MHistory
  4. ASNDAscendis Pharma A/S
    4.8%$310.4MHistory
  5. RYTMRhythm Pharmaceuticals, Inc.
    4.5%$287.2MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. KARDKardigan, Inc.
    +$195.6MNewHistory
  2. AVLNAvalyn Pharma Inc.
    +$88.1MNewHistory
  3. RLAYRelay Therapeutics, Inc.
    +$81.5MAddedHistory
  4. TNGXTango Therapeutics, Inc.
    +$80.3MAddedHistory
  5. BIIBBiogen Inc.
    +$59.7MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. KARDKardigan, Inc.
    +3.04 pp0.0% → 3.0%History
  2. SYRESpyre Therapeutics, Inc.
    +2.18 pp3.8% → 6.0%History
  3. RLAYRelay Therapeutics, Inc.
    +2.18 pp1.9% → 4.1%History
  4. AVLNAvalyn Pharma Inc.
    +1.37 pp0.0% → 1.4%History
  5. TNGXTango Therapeutics, Inc.
    +1.31 pp0.3% → 1.6%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CNTACentessa Pharmaceuticals plc
    −$208.9MSold outHistory
  2. ASNDAscendis Pharma A/S
    −$98.1MReducedHistory
  3. DYNDyne Therapeutics, Inc.
    −$44.0MReducedHistory
  4. GHGuardant Health, Inc.
    −$38.8MReducedHistory
  5. DAWNDay One Biopharmaceuticals, Inc.
    −$37.6MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CNTACentessa Pharmaceuticals plc
    −4.13 pp4.1% → 0.0%History
  2. ASNDAscendis Pharma A/S
    −2.10 pp6.9% → 4.8%History
  3. DYNDyne Therapeutics, Inc.
    −0.74 pp1.7% → 0.9%History
  4. DAWNDay One Biopharmaceuticals, Inc.
    −0.74 pp0.7% → 0.0%History
  5. PTGXProtagonist Therapeutics, Inc
    −0.69 pp2.6% → 1.9%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$6.44B
+$1.38B (+27.2%) vs. prior quarter
Positions
102
+10 vs. prior quarter
Top 10 concentration
48.9%
Top 10 as share of value
Turnover
13.4%
Q2 2026, one quarter
Average holding period
8.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $7.69B (Q2 2021)

Q1 2021: $7.52BQ2 2021: $7.69BQ3 2021: $6.86BQ4 2021: $6.47BQ1 2022: $4.81BQ2 2022: $3.18BQ3 2022: $3.44BQ4 2022: $3.47BQ1 2023: $3.38BQ2 2023: $3.44BQ3 2023: $2.97BQ4 2023: $4.47BQ1 2024: $5.67BQ2 2024: $4.14BQ3 2024: $4.66BQ4 2024: $3.59BQ1 2025: $2.82BQ2 2025: $2.67BQ3 2025: $3.46BQ4 2025: $5.46BQ1 2026: $5.06BQ2 2026: $6.44B
Q1 2021Q2 2026
13F filings of Perceptive Advisors LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 2026102$6.44BPRAXSYRECELCvs. Q1 2026SEC
Q1 2026May 29, 2026Amended92$5.06BPRAXCELCASNDvs. Q4 2025SEC
Q4 2025Feb 17, 2026112$5.46BPRAXCELCRYTMvs. Q3 2025SEC
Q3 2025Nov 14, 202591$3.46BRYTMASNDACLXvs. Q2 2025SEC
Q2 2025Aug 14, 202582$2.67BVRNAASNDACLXvs. Q1 2025SEC
Q1 2025Aug 6, 2025Amended86$2.82BVRNAACLXFOLDvs. Q4 2024SEC
Q4 2024Feb 14, 202597$3.59BVRNAACLXFOLDvs. Q3 2024SEC
Q3 2024Nov 14, 2024102$4.66BACLXNUVLFOLDvs. Q2 2024SEC
Q2 2024Aug 16, 2024Amended107$4.14BCEREFOLDACLXvs. Q1 2024SEC
Q1 2024Aug 6, 2024Amended105$5.67BCEREFOLDIOVAvs. Q4 2023SEC
Q4 2023Feb 26, 2024Amended97$4.47BCEREFOLDLIANYvs. Q3 2023SEC
Q3 2023Nov 14, 202387$2.97BFOLDCEREIMVTvs. Q2 2023SEC
Q2 2023Aug 24, 2023Amended88$3.44BFOLDCERELIANYvs. Q1 2023SEC
Q1 2023May 16, 2023Amended98$3.38BFOLDRETAAMLXvs. Q4 2022SEC
Q4 2022Feb 14, 202394$3.47BFOLDAMLXMDGLvs. Q3 2022SEC
Q3 2022Nov 14, 2022115$3.44BFOLDMRTXCEREvs. Q2 2022SEC
Q2 2022Aug 15, 2022109$3.18BTravere Therapeutics, Inc.FOLDMRTXvs. Q1 2022SEC
Q1 2022May 16, 2022135$4.81BTravere Therapeutics, Inc.FOLDSWTXvs. Q4 2021SEC
Q4 2021May 4, 2022Amended145$6.47BRetrophin IncMRTXLIANYvs. Q3 2021SEC
Q3 2021Dec 3, 2021Amended138$6.86BMRTXRetrophin IncBBIOvs. Q2 2021SEC
Q2 2021Aug 17, 2021Amended148$7.69BMRTXBBIOSWTXvs. Q1 2021SEC
Q1 2021Aug 13, 2021Amended136$7.52BMRTXBBIORetrophin Inc–SEC

13D and 13G filings

Companies where Perceptive Advisors LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

40 companies, largest stake first.

Companies where Perceptive Advisors LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
ADGMAdagio Medical Holdings, Inc.13G/A55.40%15.3M shares−2.10 ppfrom 57.50%Nov 13, 20244 filingsMay 15, 2026SEC
LONALeonaBio, Inc.13D/A19.99%1.89M shares0.00 ppfrom 19.99%Feb 8, 20219 filingsAug 25, 2026SEC
LYRALyra Therapeutics, Inc.13D/A15.55%255.8K shares–Apr 14, 20226 filingsAug 14, 2025SEC
MGTXMeiraGTx Holdings plc13D/A12.60%11.7M shares−0.30 ppfrom 12.90%May 16, 20235 filingsApr 24, 2026SEC
SLDBSolid Biosciences Inc.13D/A11.20%12.0M shares−1.70 ppfrom 12.90%Mar 23, 20219 filingsAug 14, 2026SEC
FRNMFreenome, Inc.13G10.10%10.9M sharesNewJul 23, 20261 filingJul 23, 2026SEC
IRDOpus Genetics, Inc.13G/A9.99%9.23M shares0.00 ppfrom 9.99%Mar 31, 20254 filingsAug 14, 2026SEC
ENGNenGene Therapeutics Inc.13G/A9.99%6.90M shares0.00 ppfrom 9.99%Nov 18, 20252 filingsAug 14, 2026SEC
OBIOOrchestra BioMed Holdings, Inc.13G/A9.99%5.68M shares–Sep 13, 20234 filingsNov 14, 2025SEC
ANROAlto Neuroscience, Inc.13G/A9.99%4.18M shares0.00 ppfrom 9.99%Oct 10, 20253 filingsAug 14, 2026SEC
INBXInhibrx Biosciences, Inc.13G/A9.99%1.49M shares0.00 ppfrom 9.99%Nov 14, 20243 filingsAug 14, 2026SEC
KPRXKiora Pharmaceuticals Inc13G9.99%442.4K sharesNewAug 10, 20261 filingAug 10, 2026SEC
RLAYRelay Therapeutics, Inc.13G9.99%438.5K sharesNewApr 13, 20261 filingApr 13, 2026SEC
YARWYarrow Bioscience, Inc.13G9.99%266.8K shares–Feb 16, 20214 filingsAug 3, 2026SEC
TRIBTrinity Biotech PLC13D/A9.90%3.42B shares0.00 ppfrom 9.90%Feb 9, 20249 filingsMay 4, 2026SEC
OMOutset Medical, Inc.13G9.50%5.63M shares–Feb 16, 20213 filingsFeb 28, 2025SEC
NAUTNautilus Biotechnology, Inc.13D/A9.10%11.6M shares−1.00 ppfrom 10.10%Jun 21, 20216 filingsAug 14, 2026SEC
KARDKardigan, Inc.13D8.90%8.25M sharesNewJun 25, 20261 filingJun 25, 2026SEC
RACCResearch Alliance Corp III13G8.20%750.0K sharesNewMay 28, 20261 filingMay 28, 2026SEC
XFORX4 Pharmaceuticals, Inc13G/A8.10%8.09M shares+0.80 ppfrom 7.30%Nov 3, 20253 filingsAug 14, 2026SEC
PALIPalisade Bio, Inc.13G/A7.90%14.1M shares−2.09 ppfrom 9.99%Oct 9, 20253 filingsMay 15, 2026SEC
STROSutro Biopharma, Inc.13G/A7.90%1.30M shares+2.50 ppfrom 5.40%Apr 21, 20262 filingsAug 14, 2026SEC
RACDResearch Alliance Corp IV13G7.70%700.0K sharesNewJul 20, 20261 filingJul 20, 2026SEC
IMTXImmatics N.V.13D/A7.60%11.4M shares–Jun 6, 20243 filingsAug 27, 2026SEC
AMLXAmylyx Pharmaceuticals, Inc.13G/A7.50%8.28M shares−0.70 ppfrom 8.20%Jun 21, 20228 filingsMay 15, 2026SEC

Showing the 25 largest of 40 stakes.

Latest filings

441 filings on file made by Perceptive Advisors LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Perceptive Advisors LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
NRIXNurix Therapeutics, Inc.Sep 23, 20264:30 PM ET13G5.30%5.54M sharesNewSep 16, 2026SEC
IMTXImmatics N.V.Aug 27, 20264:00 PM ET13D/A7.60%11.4M shares–Aug 26, 2026SEC
LONALeonaBio, Inc.Aug 25, 20264:00 PM ET13D/A19.99%1.89M shares0.00 ppfrom 19.99%Aug 22, 2026SEC
SLDBSolid Biosciences Inc.Aug 14, 20265:22 PM ET13D/A11.20%12.0M shares−1.70 ppfrom 12.90%Jun 30, 2026SEC
SYRESpyre Therapeutics, Inc.Aug 14, 20265:22 PM ET13G/A4.90%4.32M shares−0.10 ppfrom 5.00%Below 5%Jun 30, 2026SEC
XFORX4 Pharmaceuticals, IncAug 14, 20265:21 PM ET13G/A8.10%8.09M shares+0.80 ppfrom 7.30%Jun 30, 2026SEC
TENXTenax Therapeutics, Inc.Aug 14, 20265:21 PM ET13G/A4.50%1.70M shares−1.00 ppfrom 5.50%Below 5%Jun 30, 2026SEC
STROSutro Biopharma, Inc.Aug 14, 20265:21 PM ET13G/A7.90%1.30M shares+2.50 ppfrom 5.40%Jun 30, 2026SEC
SABSSAB Biotherapeutics, Inc.Aug 14, 20265:20 PM ET13G/A7.30%6.63M shares−1.10 ppfrom 8.40%Jun 30, 2026SEC
NVNOenVVeno Medical CorpAug 14, 20265:20 PM ET13G/A3.50%24.6K shares−6.49 ppfrom 9.99%Below 5%Jun 30, 2026SEC
NAUTNautilus Biotechnology, Inc.Aug 14, 20265:20 PM ET13D/A9.10%11.6M shares−1.00 ppfrom 10.10%Jun 30, 2026SEC
IVVDInvivyd, Inc.Aug 14, 20265:20 PM ET13G/A6.30%18.5M shares−1.60 ppfrom 7.90%Jun 30, 2026SEC
IRDOpus Genetics, Inc.Aug 14, 20265:19 PM ET13G/A9.99%9.23M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
INBXInhibrx Biosciences, Inc.Aug 14, 20265:19 PM ET13G/A9.99%1.49M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
IKTInhibikase Therapeutics, Inc.Aug 14, 20265:19 PM ET13G/A6.90%10.3M shares−2.00 ppfrom 8.90%Jun 30, 2026SEC
ENGNenGene Therapeutics Inc.Aug 14, 20265:19 PM ET13G/A9.99%6.90M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
BLSMBlossomHill Therapeutics, Inc.Aug 14, 20265:18 PM ET13G5.90%1.81M sharesNewAug 7, 2026SEC
ANROAlto Neuroscience, Inc.Aug 14, 20265:18 PM ET13G/A9.99%4.18M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
RLAYRelay Therapeutics, Inc.Aug 10, 20264:00 PM ET13G/A6.40%14.1M shares+1.10 ppfrom 5.30%Jun 30, 2026SEC
KPRXKiora Pharmaceuticals IncAug 10, 202611:59 AM ET13G9.99%442.4K sharesNewApr 6, 2026SEC